clinical trial · NCT06376045
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
AsthmaRocatinlimabPlacebo
brief summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
started
May 24, 2024
primary completion
May 14, 2026
completion
Jun 23, 2026
last updated
Jul 2, 2026
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol